Cargando…
Biomarkers of apoptosis
Within the era of molecularly targeted anticancer agents, it has become increasingly important to provide proof of mechanism as early on as possible in the drug development cycle, especially in the clinic. Selective activation of apoptosis is often cited as one of the major goals of cancer chemother...
Autores principales: | Ward, T H, Cummings, J, Dean, E, Greystoke, A, Hou, J M, Backen, A, Ranson, M, Dive, C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538762/ https://www.ncbi.nlm.nih.gov/pubmed/19238626 http://dx.doi.org/10.1038/sj.bjc.6604519 |
Ejemplares similares
-
Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs
por: Brookes, K, et al.
Publicado: (2010) -
Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer
por: Greystoke, A, et al.
Publicado: (2012) -
Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs
por: Cummings, J, et al.
Publicado: (2010) -
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
por: Murukesh, N, et al.
Publicado: (2010) -
Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma
por: Greystoke, A, et al.
Publicado: (2011)